Prevention of end-stage renal disease due to type 2 diabetes

Editorial

T H Hostetter. N Engl J Med. 2001.

. 2001 Sep 20;345(12):910-2.

doi: 10.1056/NEJM200109203451209.

No abstract available

Comment on

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. Lewis EJ, et al. N Engl J Med. 2001 Sep 20;345(12):851-60. doi: 10.1056/NEJMoa011303. N Engl J Med. 2001. PMID: 11565517 Clinical Trial.
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators. Brenner BM, et al. N Engl J Med. 2001 Sep 20;345(12):861-9. doi: 10.1056/NEJMoa011161. N Engl J Med. 2001. PMID: 11565518 Clinical Trial.
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. Parving HH, et al. N Engl J Med. 2001 Sep 20;345(12):870-8. doi: 10.1056/NEJMoa011489. N Engl J Med. 2001. PMID: 11565519 Clinical Trial.